Nature Communications (Feb 2024)

Metabolomic profiles of sleep-disordered breathing are associated with hypertension and diabetes mellitus development

  • Ying Zhang,
  • Bing Yu,
  • Qibin Qi,
  • Ali Azarbarzin,
  • Han Chen,
  • Neomi A. Shah,
  • Alberto R. Ramos,
  • Phyllis C. Zee,
  • Jianwen Cai,
  • Martha L. Daviglus,
  • Eric Boerwinkle,
  • Robert Kaplan,
  • Peter Y. Liu,
  • Susan Redline,
  • Tamar Sofer

DOI
https://doi.org/10.1038/s41467-024-46019-y
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Sleep-disordered breathing (SDB) is a prevalent disorder characterized by recurrent episodic upper airway obstruction. Using data from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), we apply principal component analysis (PCA) to seven SDB-related measures. We estimate the associations of the top two SDB PCs with serum levels of 617 metabolites, in both single-metabolite analysis, and a joint penalized regression analysis. The discovery analysis includes 3299 individuals, with validation in a separate dataset of 1522 individuals. Five metabolite associations with SDB PCs are discovered and replicated. SDB PC1, characterized by frequent respiratory events common in older and male adults, is associated with pregnanolone and progesterone-related sulfated metabolites. SDB PC2, characterized by short respiratory event length and self-reported restless sleep, enriched in young adults, is associated with sphingomyelins. Metabolite risk scores (MRSs), representing metabolite signatures associated with the two SDB PCs, are associated with 6-year incident hypertension and diabetes. These MRSs have the potential to serve as biomarkers for SDB, guiding risk stratification and treatment decisions.